|
Synonyms: Begendina&rg; (proprietary name) | BT 5/9 | SAND 26
Compound class:
Antibody
Comment: Begelomab is an investigational murine monoclonal antibody targeting DPP4 (dipeptidyl-peptidase 4, a.k.a. CD26 T cell antigen).
Peptide sequence and structural information for begelomab is available from its IMGT/mAb-DB entry. A search of patent literature reveals that the heavy chain variable region CDRs and light chain variable region CDRs of begelomab match sequences of anti-CD26 antibodies disclosed in FIG 2a of patent EP2767549 A1 [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Begelomab reached Phase clinical trial as a potential therapy for steroid-resistant acute graft versus host disease (GvHD). |
| Mechanism Of Action and Pharmacodynamic Effects |
| CD26 (DPP4) is a marker of T cell activation and is an important regulator of inflammation. CD26+ cells accumulate in the organs of patients with GvHD. Administration of an anti-CD26 antibody has been reported to decrease GvHD symptoms in a mouse model [2], making CD26 a novel target for therapeutic intervention in this disease and possibly in autoimmune diseases. |
